Tarsus Pharmaceuticals, Inc. TARS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| License fees and collaboration revenue | $16.67M— | $0— | $0— | $0— | $0— | |
| Product sales, net | $145.39M-4.1% | $151.67M+27.8% | $118.7M+15.6% | $102.66M+31.1% | $78.34M+18.0% | |
| Contractual milestone payment net sales by Product | ||||||
| Commercial Sales Milestone Payments | $102M— | —— | —— | —— | $102M-2.9% | |
| Event-Based Development Milestone | $3M— | —— | —— | —— | $3M+300% | |
| Maximum milestone payments by Product | ||||||
| Clinical Milestones | $4M0.0% | $4M0.0% | $4M0.0% | $4M0.0% | $4M0.0% | |
| Commercial and Sales Milestones | $77M0.0% | $77M0.0% | $77M0.0% | $77M0.0% | $77M0.0% | |
| Commercial Sales Milestone Payments | $92M— | —— | —— | —— | —— | |
| Milestone payments to be achieved by Product | ||||||
| Development and Regulatory Milestone | $67.5M0.0% | $67.5M0.0% | $67.5M0.0% | $67.5M0.0% | $67.5M0.0% | |
| Upon Execution of the Novation Agreement | $3.6M+44.0% | $2.5M0.0% | $2.5M0.0% | $2.5M0.0% | $2.5M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tarsus Pharmaceuticals, Inc. break its business down?
- Tarsus Pharmaceuticals, Inc. (TARS) reports total revenues by product across 2 parts — License fees and collaboration revenue and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does Tarsus Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tarsus Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
